EGFR mutations in circulating tumour DNA

The Lancet Oncology

Volumn 13, Issue 10, 2012, Pages 971-973

  Rosell, Rafael ^a,b   Molina, Miguel Angel ^b   Serrano, María Jose ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CIRCULATING TUMOR DNA; DNA; ERLOTINIB; UNCLASSIFIED DRUG;

BIOPSY TECHNIQUE; CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; DISEASE COURSE; DISEASE FREE SURVIVAL; EGFR GENE; GENE; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

DNA, NEOPLASM; HUMANS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866854802     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70369-8     Document Type: Letter

References (10)

1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
2. Schwarzenbach H, Hoon DS, Pantel K Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.
3. Narayan A, Carriero NJ, Gettinger SN, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012, 72:3492-3498.
4. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006, 12:3915-3921.
5. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009, 15:2076-2084.
6. Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011, 17:7808-7815.
7. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012, 18:2391-2401.
8. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
9. Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012, 7:115-121.
10. Brevet M, Johnson ML, Azzoli CG, Ladanyi M Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011, 73:96-102.